Gan&Lee Pharmaceuticals

Gan&Lee Pharmaceuticals (Stock abbreviation: Gan&Lee Pharmaceuticals, Stock code: 603087.SH) was established in 1998. It is a high-tech biopharmaceutical company integrating scientific research, development, production, and sales, with more than 3,200 employees worldwide. Headquartered in the southern area of Tongzhou Economic Development Zone, Beijing, within the Zhongguancun National Independent Innovation Demonstration Zone, the company owns an industrial park covering approximately 200,000 square meters. As the first company in China to master the technology for industrial-scale production of recombinant insulin analogs, Gan&Lee Pharmaceuticals holds a leading position in the Chinese diabetes market in the research, development, and production of biosynthetic human insulin and its analogs. The company has established close collaborations with well-known enterprises such as Sandoz, a subsidiary of Novartis, actively expanding into overseas markets. As a global enterprise dedicated to human health, Gan&Lee Pharmaceuticals adheres to a corporate culture of scientific rigor and excellence, committed to providing high-quality products and services to diabetes patients worldwide.